boehringer glp-1 Addressing the bigger picture in obesity and metabolic dysfunction-associated steatohepatitis Obesity in the spotlight -

doi: 10.1007/s00128-021-03283-8 62 LiM.HaoP.CaoF

These convert phosphatidylinositol2-phosphate (PIP2) into phosphatidylinositol-3-phosphate (PIP3) and, by so doing, activates protein kinase B (PKB), the metabolic pathway for glycogen synthesis.1314 In addition to the conversion to phosphatidylinositol-3-phosphate, inositol also acts by activating pyruvate dehydrogenase kinase, isoenzyme 1

It has broad-spectrum activity against focal seizures (with or without secondary generalization), myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures

In other words, it turns on: It is glucose that makes GIP receptors work

GLP-1 receptor agonists can potentially be used in some Crohn's disease patients, but inflammatory bowel disease fundamentally changes the safety and feasibility assessment